JP2022525925A5 - - Google Patents

Info

Publication number
JP2022525925A5
JP2022525925A5 JP2021556481A JP2021556481A JP2022525925A5 JP 2022525925 A5 JP2022525925 A5 JP 2022525925A5 JP 2021556481 A JP2021556481 A JP 2021556481A JP 2021556481 A JP2021556481 A JP 2021556481A JP 2022525925 A5 JP2022525925 A5 JP 2022525925A5
Authority
JP
Japan
Application number
JP2021556481A
Other languages
Japanese (ja)
Other versions
JPWO2020188348A5 (https=
JP2022525925A (ja
JP7680032B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000140 external-priority patent/WO2020188348A2/en
Publication of JP2022525925A publication Critical patent/JP2022525925A/ja
Publication of JPWO2020188348A5 publication Critical patent/JPWO2020188348A5/ja
Publication of JP2022525925A5 publication Critical patent/JP2022525925A5/ja
Application granted granted Critical
Publication of JP7680032B2 publication Critical patent/JP7680032B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556481A 2019-03-18 2020-03-17 A2/ny-eso-1特異的t細胞受容体およびその使用 Active JP7680032B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819988P 2019-03-18 2019-03-18
US62/819,988 2019-03-18
PCT/IB2020/000140 WO2020188348A2 (en) 2019-03-18 2020-03-17 A2/ny-eso-1 specific t cell receptors and uses thereof

Publications (4)

Publication Number Publication Date
JP2022525925A JP2022525925A (ja) 2022-05-20
JPWO2020188348A5 JPWO2020188348A5 (https=) 2023-03-17
JP2022525925A5 true JP2022525925A5 (https=) 2023-03-17
JP7680032B2 JP7680032B2 (ja) 2025-05-20

Family

ID=70465122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556481A Active JP7680032B2 (ja) 2019-03-18 2020-03-17 A2/ny-eso-1特異的t細胞受容体およびその使用

Country Status (7)

Country Link
US (2) US12473346B2 (https=)
EP (1) EP3941939A2 (https=)
JP (1) JP7680032B2 (https=)
CN (1) CN113906140B (https=)
AU (1) AU2020243431B2 (https=)
CA (1) CA3134102A1 (https=)
WO (1) WO2020188348A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4217738A1 (en) * 2020-09-27 2023-08-02 Genentech, Inc. High throughput multiparametric immune cell engager screening assay
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5617900A (en) 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
US20100297093A1 (en) * 2007-09-25 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Modified t cell receptors and related materials and methods
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SI2804617T1 (sl) 2012-01-17 2020-10-30 The Board Of Trustees Of The Leland Stanford Junior University Visokoafinitetni SIRP-alfa reagenti
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
EP3377523A4 (en) * 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
CN108456247A (zh) 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022525925A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)